Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases  by Buoni, Sabrina et al.
Epilepsy & Behavior Case Reports 4 (2015) 38–40
Contents lists available at ScienceDirect
Epilepsy & Behavior Case Reports
j ourna l homepage: www.e lsev ie r .com/ locate /ebcrCase ReportSevere myoclonic epilepsy of infancy: Seizure reduction during
adjunctive eslicarbazepine in two cases☆Sabrina Buoni a,⁎, Ursula Geronzi b, Alessandra Orsi a, Youssef Hayek a
a Department of Molecular Medicine and Developmental Medicine, Section of Child Neurology and Psychiatry, Azienda Ospedaliera Universitaria Senese, Policlinico Le Scotte, Siena, Italy
b Department of Molecular and Developmental Medicine, Pediatrics Section, University of Siena, Siena, Italy☆ This is an open-access article distributed under the t
Attribution-NonCommercial-No Derivative Works L
commercial use, distribution, and reproduction in any m
author and source are credited
⁎ Corresponding author at: Department of Molecular
Medicine, Section of Child Neurology and Psychiatry, Azi
Senese, Policlinico Le Scotte, Viale Bracci 1, 53100 Siena
fax: +39 0577 586150.
E-mail address: sabrinabuoni@gmail.com (S. Buoni).
http://dx.doi.org/10.1016/j.ebcr.2015.06.002
2213-3232/© 2015 Published by Elsevier Inc. This is an opa b s t r a c ta r t i c l e i n f oArticle history:
Received 14 May 2015
Received in revised form 4 June 2015
Accepted 9 June 2015
Available online 30 June 2015
Keywords:
Antiepileptic drug
Dravet syndrome
Drug-resistant epilepsy
Objective: The aim of this study was to preliminarily determine, in a short open study, the effectiveness of
eslicarbazepine acetate (ESL) in two patients with severe myoclonic epilepsy of infancy (SMEI).
Methods: We report on a 17-year-old Italian boy and a 21-year-old Italian girl with SMEI and a severe clinical
outcome, in whom we identiﬁed two mutations (5053del AA fs1685X1691 and 931GNT E311X) in the
alpha subunit of the neuronal sodium channel SCN1A gene. No drug treatment, including carbamazepine,
phenobarbital, valproate, vigabatrin, clonazepam, lamotrigine, phenytoin, nitrazepam, felbamate, zonisamide,
or lacosamide, had proven effective, and in the ﬁrst patient, a VNS pacemaker implantation was tried. The
patients suffered from severe and profound mental retardation, respectively. Seizures started in the ﬁrst year
of their life. The last EEGs showed slow background activity and paroxysmal activity in the frontal regions in
the boy and slow background activity and paroxysmal activity in the temporooccipital regions with secondary
diffusion in the girl.
Results:Weobserved in both patients after a fewweeks from the start of ESL (at a dosage of 800mgonce daily) an
important reduction in the frequency of complex partial seizures with secondary generalization.We observed an
important change in seizure frequency from two seizures during the night to one seizure in ten days in the boy
and from 6 daily seizures to one every four days with disappearance of daily seizures in the girl. The tolerability
was good, and no adverse events were observed even if ESL was added to other antiepileptic drugs.
Conclusions: Despite the short-term and open nature of our study and the small number of patients, ESL has
proven to be effective and tolerated in our cases of severe myoclonic epilepsy.
© 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Severe myoclonic epilepsy of infancy (SMEI), also known as Dravet
syndrome, is an epileptic encephalopathy that presents during the
ﬁrst year of life and is one of the most severe types of infant epilepsy
that is resistant to drugs [1,2].
Patients with Dravet syndrome display multiple seizure types
including tonic–clonic, myoclonic, absence, and focal seizures. In addi-
tion to epilepsy, SMEI is associatedwith cognitive delays and behavioral
disorders [2].erms of the Creative Commons
icense, which permits non-
edium, provided the original
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en access article under the CC BY-NCDe novo SCN1Amutations are amajor cause of SMEI [3]. In addition,
mutations in SCN1B, SCN2A, andGABRG2 also cause SMEI, and recently, a
Dravet-like phenotype in which PCDH19 and CHD2 genes are involved
was described [4,5].
Pharmacoresistance is one of themajor problems in SMEI, andmany
antiepileptic drugs do not seem to be able to control all the different
kinds of seizures, including generalized tonic–clonic seizures (GTCS)
and myoclonic, absence, and focal seizures, which characterize this
syndrome.
Eslicarbazepine acetate (ESL) is a relatively new antiepileptic drug
which has been approved in 2009 by the European Medicines Agency
and in 2013 by the US Food and Drugs Administration as adjunctive
therapy in adults with partial onset seizures with and without second-
ary generalization. Eslicarbazepine acetate shows an important action
on theblockade of voltage-gated sodiumchannel (VGSC). It has been re-
cently reported that there are some differences between AEDs acting on
VGSC that are also related to their different afﬁnities for the channel
based on the functional state of VGSC. In fact, three distinctive states
have been shown for VGSC which include the resting state, the open-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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state of these channels is similar to other AEDs (carbamazepine),
while its afﬁnity for the resting state is three times lower than the
other drugs, thus preventing sustained repetitive neural ﬁring but
disturbing physiological mechanisms to a lesser extent. Another pecu-
liarity of ESL has been reported by an experimental studywhich showed
that this drug could reduce VGSC availability through enhancement of
slow inactivation, as reported for lacosamide, while it seems not able
to alter fast inactivation of VGSC, unlike carbamazepine (CBZ) and
oxcarbazepine (OXC) [6]. In addition, the eslicarbazepinemetabolite ef-
fectively inhibited high- and low-afﬁnity CaV3.2 inward currents with
greater afﬁnity than CBZ [7].
We report a short-term open study about two patients affected by
SMEI who both showed favorable response with regard to seizure
frequency reduction when treated with ESL and good tolerability.
2. Methods
The ﬁrst patient is a 17-year-old Italian boy with SMEI and a severe
clinical outcome, in whom we identiﬁed a punctiform mutation
(5053del AA fs1685X1691) in the α subunit of the neuronal sodium
channel SCN1A gene. He started to have febrile and afebrile seizures
at the age of 6 months. No drug treatment, including valproate,
lamotrigine, carbamazepine, phenobarbital, vigabatrin, topiramate, clo-
nazepam, ethosuximide, phenytoin, felbamate, nitrazepam, ruﬁnamide,
zonisamide, or lacosamide had proven effective (Table 1). The best
results in the reduction of seizure frequency was obtained with a com-
bination of phenobarbital, clonazepam, and zonisamide, showing a re-
duction of about 50% of partial complex seizures during sleep and 70%
of daytime GTCS. During this time, the EEGs and clinical and epileptic
characteristics of this patient showed typical features of SMEI such as
slowing of background EEG activity with multifocal and diffuse dis-
charges prevalent in the frontal regions, myoclonic seizures at the age
of 2 years and 6 months, ataxia, and progressive intellectual disability.
At the age of 16 years and 6 months, we added ESL in combination
with phenobarbital, clonazepam, and zonisamide at the initial dosage
of 400 mg once daily and after two weeks at 800 mg/day. After just a
few weeks from the start of therapy, we observed a complete response
with disappearance of monthly GTCS and sleep frontal-partial complex
seizures (with 3–4 occurrences per night previously observed). We did
not observe adverse events during the treatment period of six months
with a signiﬁcant improvement in behavior, particularly oppositional
deﬁant disorder and the maintenance of attention.Table 1
Response and time of administration of AEDs in both patients.
AEDs Time of administration
Patient 1: 17-year-old boy Patient 2: 20-year-ol
Valproate 2 years 18 years
Lamotrigine 6 months 5 months
Clonazepam 10 years 12 years
Carbamazepine 9 months 6 months
Phenobarbital 12 years 1 month
Vigabatrin 3 months 4 months
Topiramate 1 month 6 months
Ethosuximide 1 year 8 months
Phenytoin 2 months 10 years
Felbamate 1 month 3 months
Nitrazepam 3 months 2 months
Ruﬁnamide 2 months 3 months
Zonisamide 4 years 4 months
Lacosamide 3 months 1 month
Acetazolamide 4 months 6 months
Stiripentol 4 months 4 months
VNS –
Eslicarbazepine 6 months 6 months
a Number of daily seizures: 0= increased daily seizures; 1= unchanged seizures; 2= reduc
of frequency); 4 = reduction of seizures (more than 70% of frequency).The second patient is a 21-year-old Italian girl. At the age of 11, we
had identiﬁed a punctiformmutation (931GNT E311X) in theα subunit
of the neuronal sodium channel SCN1A gene. The febrile and afebrile
complex-partial seizures started at the age of 3 months.
Similar to the ﬁrst patient, the drug treatment for this patient
included acetazolamide and stiripentol that had not been proven
effective (Table 1). In particular, at the age of 8, a combination of pheno-
barbital, clonazepam, and acetazolamide (250 mg/day) caused a
decrease in seizure frequency of about 40%. The number of seizures
was previously much higher and associated with several eyelid
myoclonic seizures at a frequency of hundreds of occurrences daily
and several massive myoclonias from the age of 3 years. Magnetic
resonance imaging showed moderate brain atrophy, which did not
progress during maturation, and brain interictal SPECT at the age of 2
showedhypoperfusion of the left frontal cortex. The EEG showeddiffuse
and multifocal paroxysmal activity that was more evident in the
bioccipital regions. In the ﬁrst year of life, the child showed unimpaired
neuromotor development and hypotonia. She presented progressive
intellectual disability, which became profound, as well as severe ataxia,
making it impossible for her towalk. In addition, her speechwas absent.
At the age of 10, a VNS device was implanted without any results.
At the age of 20, we added eslicarbazepine acetate to phenytoin,
clonazepam, and valproate at the initial dosage of 400 mg once daily,
which was increased after two weeks to 800 mg/day. We have also
observed in this case good response with regard to seizure frequency
reduction in just a few weeks after starting therapy. The girl does not
present any daily seizures, just one seizure every four days currently.
3. Results
Weobserved a signiﬁcant and fast effect using ESL as add-on therapy
to other AEDs in both patients similar towhatwas reported in literature
for adult patients with partial-onset seizures [8]. The peculiarity in our
caseswas the agewhen ESL therapywas started, 16 years and 6months
for the boy and 20 years for the girl, respectively, underlying the possi-
bility of using ELS with good efﬁcacy as an add-on therapy in young pa-
tients [9]. Of particular interest is ESL's efﬁcacy in both patients with
SMEI carrying SCN1A mutation because it is well known that seizure
control is very difﬁcult to achieve in this syndrome. The reason why
ESL was effective in patients whose seizures are typically drug-
resistant is not yet known; we could theorize that it could be due to
the peculiar action of ESL on VGSC. Indeed, carbamazepine, which alters
fast inactivation of VGSC, can worsen seizures and should not be used inResponsea
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tion of seizures (less than 50% of frequency); 3= reduction of seizures (less than 50–70%
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been used in combinationwith different AEDs, although benzodiazepine
was the only AED common in both cases. Thus, it does not seemplausible
that the effectiveness of ESL in patients with SMEI is attributable to the
association betweendifferentdrugs, but by analyzing the drugs in partic-
ular, we can observe their similar mechanisms, especially those on
GABAergic system and voltage-gated sodium channel. Another peculiar-
ity of our report is the effective dose of ESL, which was a low recom-
mended dosage. Moreover, we observed a fast response to the initial
dose of ESL [10].
4. Conclusions
Adjunctive eslicarbazepine led to seizure reduction in two patients
with severe myoclonic epilepsy of infancy. Although this is a short-
term open study, the results are promising but need conﬁrmation.
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